Navigation Links
Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?

New Rochelle, NY, July 26, 2012 Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc. (, explores whether or not this regimen is still the most effective. The article is available free online at the Cancer Biotherapy and Radiopharmaceuticals website (

In the article "Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?" ( Robert Dillman and colleagues at the Hoag Institute for Research and Education and Hoag Family Cancer Institute, Newport Beach, CA concluded that until long-term survival data for some of the newer drugs are available, patients with stage IV metastatic melanoma who are well enough to be given intensive IL-2 therapy should receive it initially, either alone or in combination with one of the newer therapeutic agents.

"This is an important article that puts into perspective the reasons why IL-2 should continue to be the initial therapy in patients with metastatic melanoma," says Editor Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham.

Contact: Vicki Cohn
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News

Page: 1

Related biology news :

1. Happy Fathers Day! Another reason why dads and hopeful dads should quit smoking now
2. Countries should implement inclusive wealth accounting
3. President, CEO Leppävuori, VTT: Finland should create a national bioeconomy strategy
4. Reproductive health providers should discuss environmental exposure risks with patients
5. Should we play hide-and-go-seek with our childrens vegetables?
6. Global CO2 emissions continue to increase
7. Cell Press journals continue to deliver high impact
8. Monarch butterflies down again this year as decline continues, says Texas A&M expert
9. Powerful class of antioxidants may be potent Parkinsons treatment
10. ECGs administered by paramedics can speed treatment for severe heart attacks
11. Reorganizing brain could lead to new stroke, tinnitus treatments
Post Your Comments:
Related Image:
Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?
(Date:12/1/2015)... JOSE, Calif. , Dec. 1, 2015 ... of human interface solutions, today announced a new agreement ... enable OEMs with real-world test and development environments that ... Labs solutions. The partnership reduces the complexity of FIDO ... and software permits Synaptics and OEMs to verify FIDO ...
(Date:11/30/2015)... DEERFIELD BEACH, Fla. , Nov. 30, 2015 ... selected as a finalist in this year,s Fierce Innovation ... publisher of FierceHealthIT , ... BIOCLAIM was recognized as a finalist in the ... --> ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Capacitive Fingerprint Sensors - Technology and ... --> --> ... market, especially in smartphones. The fingerprint sensor vendor Idex ... fingerprint sensor units in mobile devices and of the ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... OXFORD, England , December 1, 2015 ... Touch is a touch activated lancet that features Owen ... Vancouver , booth 1403, Unistik® Touch is a ... Zone Technology®. --> Owen Mumford, a leading ... its range of medical devices, available initially in the ...
(Date:12/1/2015)... SEATTLE , Dec. 1, 2015 Today ... headquarters in Seattle,s South Lake ... northwest corner of Mercer Street and Westlake Avenue North, ... to the Allen Institute for Brain Science and the ... Allen , philanthropist and founder of the Allen Institute. ...
(Date:12/1/2015)... -- Researchers at the Broad Institute of MIT and ... MIT have engineered changes to the revolutionary CRISPR-Cas9 genome ... errors. The refined technique addresses one of the major ... Science , Feng Zhang and his ... amino acids that make up the Cas9 enzyme from ...
(Date:12/1/2015)... Dec. 1, 2015  Twist Bioscience, a company focused on ... , Ph.D., has been selected as one of Foreign ... fast-tracking the building blocks of life . Each year, ... whose contributions and work have changed lives and are shaping ... "It is an honor to be recognized among these incredible ...
Breaking Biology Technology: